Can Moderna or the rest of the vaccine makers survive RFK's Vaccine Crackdown During a Global Selloff
The pharmaceutical gravy train might just be screeching to a halt. With all their billions and political lobbyists Big Pharma thought they were untouchable? Think again. RFK is striking fear into the hearts of Moderna, Pfizer, AstraZeneca, Johnson & Johnson, and the rest of the vaccine cartel. And let's be honest, they've had it coming.
COVID-19 was a cash cow for these players. Billions upon billions of taxpayer dollars were funneled into these corporate coffers, all under the guise of "public health." But now, with RFK Jr. sniffing around, the stench of corruption is becoming too pungent to ignore. The man isn't playing nice. He's calling out the regulatory revolving door between Big Pharma and the FDA, and the outright lies peddled to a terrified public.
And what about those "safe and effective" vaccines? The ones that mysteriously coincided with a surge in adverse events? The ones that Big Pharma swore up and down had no long-term effects? Well, the chickens are coming home to roost, and RFK Jr. is holding the pitchfork. Pfizer, with their endless booster campaigns, AstraZeneca, with their clotting controversies, and JNJ, with their own share of safety concerns, are all feeling the heat.
The real kicker? This isn't just about vaccines anymore. The winds are shifting. The public is waking up. They're realizing that maybe, just maybe, pumping everyone full of experimental mRNA jabs wasn't the smartest move. And as the vaccine narrative crumbles, the spotlight is turning towards something far more interesting: broad-spectrum antivirals.
You see, while Moderna, Pfizer, AstraZeneca, and JNJ were busy raking in profits from their one-size-fits-all "solutions," smaller players were quietly working on technologies with the potential to revolutionize viral treatment. We're talking about a company like Nanoviricides (NASDAQ: NNVC) that has broad spectrum antivirals that can BIND, ENGULF, and DESTROY. It's called a cellular mimic that has all the cellular receptors sitting on a small patch of nanoparticle membrane that sticks like fly paper to the invading virus forming a cocoon that ultimately dissolves it. They claim to have a broad spectrum antiviral that they are testing on a number of viruses like COVID-19, H5N1, RSV, Measles, Singles, HIV, and Influenza. They finished a phase 1a in covid-19 and had good safety results. They are expanding to a phase 2 and going after a number of viruses. Sounds ideal until you realize it can only be given intravenously.
The one therapeutic that should have been highlighted by the government years ago for their near perfect clinical trial in COVID-19 is Bioxytran’s (OTC: BIXT). They developed a chewable galectin antagonist tablet. Now this isn’t just your run of the mill antiviral that stops the replication of the virus inside the cell. It works by blocking the virus from entering the cell altogether. Scientists call this an entry inhibitor but to the rest of the human race this is quite literally the end of the jab.
They had statistically significant phase 2 results with 100% efficacy vs 6% in placebo. Unfortunately they have been in stasis for the past 2 years while the Big Pharmas gorged on vaccines revenues and government grants. The good news for investors following this story is that their market cap is a tiny $13 million which is at a stupid cheap entry level for a company with a patent on this tech for 60+ viruses. Their time is now as the word faces the inevitable jump of H5N1 Bird Flu to humans. They recently announced their intent to prevent mass bird flu infection in chickens by using a modification of their drug as a prophylactic. Bioxytran is trying to take one of the most efficacious antivirals ever made and adapt it for animal use. These aren't your run-of-the-mill antivirals. They are precision weapons, designed to tackle viruses at their core, without the collateral damage found in traditional pharmaceuticals.
And here's the real kicker: these technologies could render the entire vaccine paradigm obsolete. Why inject healthy people with potentially harmful substances when you can treat viral infections directly, with minimal side effects? Big Pharma knows this, and they're terrified which puts both of these companies on the potential acquisition list of 5 of the top vaccine makers. .
Because let's face it, their business model is built on repeat customers. Sick people are profitable people. Healthy people? Not so much. So, as RFK Jr. dismantles the vaccine industrial complex, these smaller players, with their innovative technologies, could be poised to swoop in and pick up the pieces.
Will Moderna, Pfizer, AstraZeneca, and JNJ survive? That remains to be seen. But one thing's for sure: the landscape is changing, and the old guard is about to face a reckoning. And while they're busy scrambling to protect their profits, the real winners might just be the companies offering real solutions, not just endless injections.